Quantum Biopharma Ltd. (QNTM) Form 6-K — Sep 17, 2026
Quantum BioPharma filed a Form 6-K furnishing ten press releases issued between March 2025 and August 2026, the most substantive being its audited FY2025 results, which maintained a 'no going concern' status with $11.3 million USD of cash and digital assets and management-stated runway beyond January 2028. The FY2025 release shows operating expenses down to $15.3 million USD from $16.1 million, trade payables cut roughly in half to $2.0 million, and completed Lucid-MS Phase 1 toxicity studies showing no toxicity, keeping the multiple sclerosis candidate on track for a Phase 2 IND filing in the first half of 2026.
Key figures
- Debt Amount
- Up to C$4.0 million proposed convertible debenture offering (4,000 units at C$1,000 each); earlier fourth tranche closed March 2025 for $100,000 (100 units)
- Cash Position
- USD $11.3 million (cash on hand plus fair market value of digital assets as of the FY2025 financial statement filing date)
- Interest Rate
- 1.25% per month on convertible debentures (~15% annualized)
- Maturity Date
- 24 months from date of issuance (debentures)
- Cash Runway
- Management believes sufficient cash to sustain basic operations beyond January 2028
- Trade Payables
- Reduced ~50% from $4.1 million (Dec 31, 2025) to $2.0 million as of filing date
- Unbuzzd Ownership
- 19.48% as of June 30, 2026, down from 25.71% as of June 30, 2024 and 19.84% as of December 31, 2025
- External Rn DFY2025
- USD $2.8 million vs $6.1 million in FY2024
- Gna Expenses FY2025
- USD $9.0 million vs $9.4 million in FY2024
- Tax Loss Carryforward
- ~C$130 million
- Unbuzzd Reg DOffering
- Up to $5.0 million USD Reg D 506(c) offering; MNP engaged as auditors for possible IPO
- Unbuzzd Royalty Terms
- 7% of sales until payments total $250 million, then 3% in perpetuity
- Insider Voting Control
- Class A multiple voting shares restored to ~75.27% of aggregate voting rights post-placement; Durkacz joint actors hold ~23.77% of total voting rights after 77,000-share transfer
- Ir Marketing Contracts
- Senergy USD $150,000 + King Tide Media USD $125,000 + FinnCom USD $170,500 (~USD $445,500 total)
- Debenture Revised Terms
- Conversion price cut to C$3.00 from C$4.00; warrants increased to 333.33 per unit; warrant exercise price cut to C$3.75 from C$5.00 (March 11, 2026)
- Options Granted Aug2026
- 572,500 stock options at C$4.80, 5-year term expiring August 20, 2031; 172,500 vested immediately
- Class AInsider Placement
- Up to 30 Class A multiple voting shares at $25 each for up to $750, subscribed by entities of CEO Zeeshan Saeed and director Anthony Durkacz
- Debt Settlement July2026
- CAD$123,487.43 settled via issuance of 30,948 Class B shares at CAD$3.99
- Operating Expenses FY2025
- USD $15.3 million vs $16.1 million in FY2024 (~5% improvement)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.